A new clinical trial is evaluating selinexor, a non-JAK inhibitor, as a first-line therapy in myelofibrosis, with a JAK inhibitor added later only if needed. This innovative sequencing challenges the current, long-standing paradigm of initiating all treatments with a JAK inhibitor.

Clinicians can reassure myelofibrosis patients that the drop in hemoglobin often seen when starting ruxolitinib does not carry the same negative prognostic weight as anemia caused by the disease itself. This distinction is crucial for managing patient expectations and continuing effective therapy despite initial side effects.

While beneficial for patients with prior weight loss, ruxolitinib can cause significant weight gain (20-30 pounds) in other myelofibrosis patients. This quality-of-life issue should be discussed proactively, as it can become a major concern, effectively trading one disease state for another.

For myelofibrosis patients with profound splenomegaly but only moderate thrombocytopenia (platelets 50k-100k), fedratinib may be the best frontline option. It is arguably the most potent JAK inhibitor for spleen reduction and is approved for use in patients with platelet counts as low as 50,000.

Interferon therapy is being evaluated in a distinct niche from JAK inhibitors. It is targeted at patients with early or low-risk myelofibrosis, not for immediate symptom control, but with the strategic goal of potentially modifying the disease course and slowing its natural progression.

The anemia seen in myelofibrosis patients on ruxolitinib is not just a drug side effect but an interaction with the underlying disease. This is proven by the fact that polycythemia vera patients on the same drug do not become anemic, showing the myelofibrotic marrow is uniquely susceptible to the drug's effects.

For myelofibrosis patients with both anemia and splenomegaly, a practical approach is to start with ruxolitinib for its superior symptom control. If the subsequent anemia is not well-tolerated, switching to momelotinib allows for a more informed, personalized decision based on the patient's experience with both agents.

Contrary to the assumption that two drugs are always more toxic than one, the Lenvatinib-Belzutifan combination in the LightSpark-011 trial presented a different, but not quantifiably worse, toxicity profile compared to cabozantinib monotherapy, challenging conventional thinking on combination therapy side effects.

The LEAP-010 trial showed a combination therapy improved tumor response and progression-free survival but failed to improve overall survival, the ultimate measure of benefit. This highlights the risk of relying on surrogate endpoints, which can be misleading, especially when a treatment adds significant toxicity.